Table 3.
The association of MUC16 and mesothelin expression with pathologic factors in patients with pancreatic ductal adenocarcinoma
| Number | MUC16 high/mesothelin high group | Other group | P | |
|---|---|---|---|---|
| 41 | 62 | |||
| Differentiation | ||||
| Well/ moderate | 93 | 35 | 57 | 0.1908 |
| Poor | 10 | 6 | 4 | |
| Tumor size | ||||
| >40mm | 16 | 12 | 4 | 0.0041 |
| ≤40mm | 87 | 29 | 58 | |
| Local progression | ||||
| Intrapancreatic common bile duct invasion | ||||
| Positive | 22 | 6 | 16 | 0.1757 |
| Negative | 81 | 35 | 46 | |
| Duodenal invasion | ||||
| Positive | 40 | 12 | 28 | 0.1052 |
| Negative | 63 | 29 | 34 | |
| Serosal invasion | ||||
| Positive | 74 | 35 | 39 | 0.0131 |
| Negative | 29 | 6 | 23 | |
| Retropancreatic tissue invasion | ||||
| Positive | 85 | 35 | 50 | 0.5369 |
| Negative | 18 | 6 | 12 | |
| Portal venous system invasion | ||||
| Positive | 25 | 13 | 12 | 0.1523 |
| Negative | 78 | 28 | 50 | |
| Arterial system invasion | ||||
| Positive | 5 | 4 | 1 | 0.0803 |
| Negative | 98 | 37 | 61 | |
| Extrapancreatic nerve plexus invasion | ||||
| Positive | 33 | 16 | 17 | 0.2166 |
| Negative | 70 | 25 | 45 | |
| Invasion of other organs | ||||
| Positive | 6 | 5 | 1 | 0.0356 |
| Negative | 97 | 36 | 61 | |
| Lymphatic permeation | ||||
| Positive | 88 | 39 | 49 | 0.0250 |
| Negative | 15 | 2 | 13 | |
| Vascular permeation | ||||
| Positive | 64 | 28 | 36 | 0.2948 |
| Negative | 39 | 13 | 26 | |
| Perineural invasion | ||||
| Positive | 76 | 29 | 47 | 0.5665 |
| Negative | 27 | 12 | 15 | |
| Lymph node metastasis | ||||
| Positive | 69 | 32 | 37 | 0.0523 |
| Negative | 34 | 9 | 25 | |